Corbus Pharmaceuticals (CRBP) CFO sells 4,701 shares under plan

Rhea-AI Filing Summary

Corbus Pharmaceuticals Holdings, Inc. Chief Financial Officer Sean F. Moran reported an open-market sale of 4,701 shares of common stock at a weighted average price of $7.783 per share. After this sale, he directly holds 96,694 shares, including 68,795 unvested restricted stock units.

The transaction was executed under a pre-arranged Rule 10b5-1 trading plan and was used to cover tax withholding obligations arising from the vesting and settlement of RSUs. The sale was mandated by the company’s “sell to cover” election and is described as non-discretionary for the executive.

Insider Trade Summary

Net Seller: 4,701 shares ($36,588)

Net Sell 1 txn

Insider Moran Sean F.

Role Chief Financial Officer

Sold 4,701 shs ($37K)

Type	Security	Shares	Price	Value
Sale	Common Stock, par value $0.0001 per share	4,701	$7.783	$37K

Holdings After Transaction: Common Stock, par value $0.0001 per share — 96,694 shares (Direct)

Footnotes (1)

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025 and the sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.58 to $7.96. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. This amount includes 68,795 unvested RSUs subject to each grant's vesting schedule as previously reported.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Moran Sean F.

(Last) (First) (Middle)

C/O CORBUS PHARMACEUTICALS HOLDINGS, INC

500 RIVER RIDGE DRIVE

(Street)

NORWOOD MA 02062

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Corbus Pharmaceuticals Holdings, Inc. [ CRBP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.0001 per share	02/13/2026		S(1)		4,701	D	$7.783(2)	96,694(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025 and the sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.58 to $7.96. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. This amount includes 68,795 unvested RSUs subject to each grant's vesting schedule as previously reported.

	/s/ Sean Moran	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Corbus Pharmaceuticals (CRBP) disclose in this Form 4 filing?

Corbus Pharmaceuticals reported that Chief Financial Officer Sean F. Moran sold 4,701 shares of common stock. The sale was executed under a Rule 10b5-1 trading plan to satisfy tax withholding obligations tied to vesting restricted stock units, rather than as a discretionary sale.

How many Corbus Pharmaceuticals (CRBP) shares did the CFO sell and at what price?

The CFO sold 4,701 shares of Corbus Pharmaceuticals common stock at a weighted average price of $7.783 per share. Footnotes state the transactions occurred in a price range between $7.58 and $7.96 across multiple trades on the reported transaction date.

Why did the Corbus Pharmaceuticals (CRBP) CFO sell shares in this transaction?

The filing states the sale covered tax withholding obligations from the vesting and settlement of restricted stock units. The company elected to satisfy these taxes via a “sell to cover” transaction, meaning the sale did not represent a discretionary decision by the CFO.

Was the Corbus Pharmaceuticals (CRBP) CFO’s stock sale part of a 10b5-1 plan?

Yes. The transaction was effected under a Rule 10b5-1 trading plan adopted on March 14, 2025. Such plans pre-schedule trades, and the filing explains that this sale followed the plan and the issuer’s tax withholding election, limiting the executive’s discretion.

How many Corbus Pharmaceuticals (CRBP) shares does the CFO hold after this sale?

After the reported sale, the CFO directly holds 96,694 shares of common stock. The filing notes this amount includes 68,795 unvested restricted stock units, which remain subject to their existing vesting schedules as previously disclosed in earlier reports.

What additional details are provided about the Corbus Pharmaceuticals (CRBP) trade prices?

The reported sale price of $7.783 per share is a weighted average. Footnotes explain the 4,701 shares were sold in multiple transactions, with individual trade prices ranging between $7.58 and $7.96, and more detailed breakdowns are available upon request.